Metabolic Research
BioHarmony verdict
Worth trying
Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds because benefits often require indefinite use and rare severe harms remain unresolved.
Read full reportSemaglutide is a prescription GLP-1 receptor agonist used for type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with established CVD and overweight or obesity, and newer metabolic indications such as noncirrhotic MASH with fibrosis. In practice, semaglutide is best known as Ozempic for type 2 diabetes, Wegovy for obesity and cardiometabolic risk reduction, and Rybelsus as the oral tablet.
From the BioHarmony report, reviewed 2026-09-08.
Activates GLP-1 receptors in pancreatic beta cells, appetite-regulating hypothalamic circuits, and the GI tract, increasing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying, and suppressing appetite.
Full risk profile in the BioHarmony report.
No approved-label or study protocol is recorded for Semaglutide (GLP-1 Agonist) yet.
Members can compare additional reported doses, schedules, and preparation notes.
Attributed viewpoints, separate from primary research.
These entries name compounds evaluated together in a human study. They are not instructions to combine treatments.
A randomised human trial evaluated this fixed combination against its component therapies. That makes it a co-studied relationship, not a DIY pairing or a recommendation to combine medicines.
REIMAGINE 2 randomised trial, 2026Sources are still being reviewed for this compound.
Free guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.